Navigation Links
Alimera Reports Results From the Six-Month Interim Readout of the Human PK Iluvien(TM) Study
Date:10/1/2008

ATLANTA, Oct. 1 /PRNewswire/ -- Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported the interim month six safety and efficacy results from the first human pharmacokinetic (PK) study of Iluvien(TM).

Iluvien is an intravitreal insert being developed for the treatment of diabetic macular edema (DME). DME is a disease of the retina, which affects individuals with diabetes and can lead to severe vision loss and blindness. Each Iluvien insert is designed to provide a sustained therapeutic effect, up to 36 months for the low dose and up to 24 months for the high dose. Iluvien is inserted into the patient's eye with a 25-gauge needle, which allows for a self-sealing wound. This insertion is very similar to an intravitreal injection, a procedure commonly employed by retinal specialists.

This 36-month, open-label, Phase 2 PK study, running concurrently with the pivotal Phase 3 FAME(TM) Study of Iluvien (Fluocinolone Acetonide in Diabetic Macular Edema), is designed primarily to assess systemic exposure of the corticosteroid, fluocinolone acetonide, after administration of Iluvien in patients with DME. Secondarily, the PK study is designed to provide information on the safety and efficacy of Iluvien in a DME patient population. A total of 37 subjects were enrolled in the PK study, 20 patients on the low dose of Iluvien (an approximate 0.23 micrograms per day dose), and 17 patients on the high dose of Iluvien (an approximate 0.45 micrograms per day dose).

The six-month interim readout from the PK study showed 18 percent of the high dose patients had an improvement in best corrected visual acuity (BCVA) of 15 letters or greater over baseline. This is consistent with the three- month readout. The percentage of low dose patients that had an improvement in BCVA of 15 letters or greater from baseline decreased from
'/>"/>

SOURCE Alimera Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. DSMB Again Supports Continuation of Alimera Sciences Phase 3 Clinical Trial of Iluvien(TM) for the Treatment of DME
2. Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study
3. BioView Reports Interim Results of Early Detection Lung Cancer Diagnostic Test
4. Bioheart Reports Promising Results From Preclinical Study of Adipose-Derived Acute Cell Therapy
5. MannKind Reports Positive Data from a Phase 3 Clinical Study of Technosphere Insulin in Type 1 Diabetes
6. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
7. Nutrition 21 Reports That National Toxicology Program Studies Support the Safety of Chromium Picolinate
8. Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma
9. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
10. Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin
11. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... 1, 2015  Shares of Aerie Pharmaceuticals, Inc. (NASDAQ: ... yesterday following the results of the Phase 3 Rocket ... the trial failing to meet its end points, compelling ... come from future studies. An analyst report ... pipeline, financial review, analyst summary, valuation, and recommendation can ...
(Date:4/30/2015)... 2015  Accuray Incorporated (Nasdaq: ARAY ) ... with MIM Software Inc. to further develop adaptive ... ® product portfolios. The new software solution ... is Accuray,s second collaboration with MIM; the previous ... iPad-based treatment plan review capability, PlanTouch™. ...
(Date:4/30/2015)...   Regulus Therapeutics Inc . (NASDAQ: RGLS ... of innovative medicines targeting microRNAs, today announced that it ... ended March 31, 2015 on Thursday, May 7, 2015, ... Regulus will host a conference call and webcast on ... Time to discuss its first quarter 2015 financial results ...
Breaking Medicine Technology:All is Not Lost for Aerie Pharmaceuticals - VLM Research Issued by BrokerBank Securities, Inc. 2Accuray Signs Agreement with MIM Software Inc. to Develop Adaptive Therapy Software 2Accuray Signs Agreement with MIM Software Inc. to Develop Adaptive Therapy Software 3Regulus Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call 2Regulus Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call 3
(Date:5/3/2015)... Indiana Fiber Network, LLC (IFN), the leading ... Inc (BCS) has selected IFN as a fiber transport ... service, and working relationship with IFN has been great, ... you get with IFN. I like dealing with ... decisions and operates as a local community business partner.” ...
(Date:5/3/2015)... (PRWEB) May 03, 2015 SpineFrontier, a ... from the FDA to produce and market their new ... can be used in outpatient settings and is compatible ... alternate posterior approach has been extensively researched and refined ... approval to use this approach in conjunction with a ...
(Date:5/2/2015)... NV (PRWEB) May 02, 2015 Ticket Down ... tickets for the long awaited event today, Saturday, May ... Diehard boxing fans will be able to secure tickets ... , The fight that boxing fans have wanted for more ... months ago. Floyd “Money” Mayweather will step inside the ring ...
(Date:5/2/2015)... May 02, 2015 It’s a pattern ... natural disaster strikes anywhere on this planet, cyber scammers ... sympathy and compassion for their own personal gain. ... Emergency Readiness Team) issued an alert titled “Nepal ... email scams citing the earthquake in Nepal. The scam ...
(Date:5/2/2015)... Kare Visits LLC. launched in Chicago in ... Kare Visits offers relief for caregivers by visiting loved ... According to the Caregiver Action Network, eight in ten ... hours a week caring for an elderly or disabled loved ... a nurse, a caregiver is now empowered to schedule an ...
Breaking Medicine News(10 mins):Health News:Bank Computer Services, Inc Selects Indiana Fiber Network, LLC as Fiber Transport Provider 2Health News:Bank Computer Services, Inc Selects Indiana Fiber Network, LLC as Fiber Transport Provider 3Health News:Cheap Floyd Mayweather vs. Manny Pacquiao Tickets: Ticket Down Has Last Minute Tickets for Mayweather vs. Pacquiao at the MGM Grand Garden Arena in Las Vegas 2Health News:Cheap Floyd Mayweather vs. Manny Pacquiao Tickets: Ticket Down Has Last Minute Tickets for Mayweather vs. Pacquiao at the MGM Grand Garden Arena in Las Vegas 3Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 2Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 3Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 4Health News:Chicagoan Seeks to Transform Industry by Launching an Innovative Elderly Care Solution 2
... ... affordable drug and alcohol rehab programs. Mountainside in Connecticut cites a sharp increase in demand ... increase in alcoholic binge drinking, drug abuse and marital problems. , ... (PRWEB) December 3, 2009 -- Mountainside Affordable Addiction Treatment ...
... Dec. 3 The American Association for Cancer Research (AACR) ... date on passive smoking and breast cancer in women conducted ... , Study data revealed that women who never smoked ... a lifetime--especially during adulthood--had a significantly increased breast cancer risk ...
... , PASADENA, Calif., ... businesses, the risk of disability remains one of the most ... but also their business,s viability. , "As the recession ... businesses are recognizing the need to shore up their financial ...
... , WAYNE, Pa., Dec. ... InterComponentWare Inc. (ICW), a global leader in eHealth technology, to ... Exchange (HIE). ICW will implement its Enterprise Master Patient ... (IPF) across 6 counties, 470,000 residents, 8 hospitals, and over ...
... replicating in the livers of primates , , THURSDAY, Dec. ... C has shown promise in a primate study. , The ... hepatitis C virus from replicating. Unlike other antivirals that target ... RNA molecule in the liver that hepatitis C needs to ...
... The following is being released by Common Cause ... Patrick Leahy (D-Vt.) is offering an amendment to the ... insurance industry,s legal exemptions for violations such as price ... fiercely opposes the repeal, which would subject health insurance ...
Cached Medicine News:Health News:Economic Crisis Causes Acute Demand for Affordable Drug Addiction Treatment 2Health News:Northern California Cancer Center's Findings on Breast Cancer and Secondhand Smoke Released Internationally by the American Association for Cancer Research 2Health News:New Disability Income Insurance Options Provide More Choice for California's Small Business Owners 2Health News:New Disability Income Insurance Options Provide More Choice for California's Small Business Owners 3Health News:New Disability Income Insurance Options Provide More Choice for California's Small Business Owners 4Health News:Southern Tier HealthLink NY Selects InterComponentWare to Deliver Core Components of HIE 2Health News:New Hepatitis C Treatment Shows Promise 2Health News:New Hepatitis C Treatment Shows Promise 3Health News:Health Insurance Industry Once Again Hoping Investment Pays Off 2Health News:Health Insurance Industry Once Again Hoping Investment Pays Off 3Health News:Health Insurance Industry Once Again Hoping Investment Pays Off 4Health News:Health Insurance Industry Once Again Hoping Investment Pays Off 5Health News:Health Insurance Industry Once Again Hoping Investment Pays Off 6Health News:Health Insurance Industry Once Again Hoping Investment Pays Off 7Health News:Health Insurance Industry Once Again Hoping Investment Pays Off 8
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: